



General Assembly

January Session, 2019

Raised Bill No. 820

LCO No. 3685



Referred to Committee on HUMAN SERVICES

Introduced by:
(HS)

***AN ACT WAIVING PRIOR MEDICAID AUTHORIZATION
REQUIREMENTS FOR CERTAIN PHARMACOGENOMICS TESTS.***

Be it enacted by the Senate and House of Representatives in General Assembly convened:

1 Section 1. (NEW) (*Effective July 1, 2019*) (a) For purposes of this
2 section, (1) "pharmacogenomics" means the study of how an
3 individual's genetic makeup, or genotype, affects the body's response
4 to prescription drugs, and (2) "medically necessary" means a
5 determination by a treating primary care practitioner made in
6 accordance with section 17b-259b of the general statutes.

7 (b) The Commissioner of Social Services shall provide Medicaid
8 coverage, to the extent permissible under federal law, for
9 pharmacogenomics tests determined to be medically necessary. The
10 commissioner shall not require prior authorization for medically
11 necessary pharmacogenomics tests for persons being treated for (1)
12 behavioral disorders, (2) psychiatric disorders, (3) cardiovascular
13 disorders, and (4) chronic pain.

14 (c) In contracting with a provider for the provision of

15 pharmacogenomics tests, the commissioner may give preference to any
16 Medicaid-enrolled laboratory provider that offers a discounted price
17 for such tests. If necessary, the commissioner shall amend the
18 Medicaid state plan to provide coverage for pharmacogenomics tests.

This act shall take effect as follows and shall amend the following sections:		
Section 1	<i>July 1, 2019</i>	New section

Statement of Purpose:

To waive prior Medicaid authorization requirements for certain pharmacogenomics tests.

[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]